Avacta Group Plc (AVCTF)
USD 0.52
(0.0%)
USD 0.52
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 23.24 Million GBP | 140.83% |
| 2022 | 9.65 Million GBP | 228.22% |
| 2021 | 2.94 Million GBP | -19.11% |
| 2020 | 3.63 Million GBP | -11.81% |
| 2019 | 4.12 Million GBP | 49.22% |
| 2018 | 2.76 Million GBP | 1.02% |
| 2017 | 2.73 Million GBP | 26.33% |
| 2016 | 2.16 Million GBP | 19.42% |
| 2015 | 1.81 Million GBP | -42.99% |
| 2014 | 3.18 Million GBP | 17.78% |
| 2013 | 2.7 Million GBP | -13.74% |
| 2012 | 3.13 Million GBP | 28.02% |
| 2011 | 2.44 Million GBP | 18.29% |
| 2010 | 2.06 Million GBP | 118.96% |
| 2009 | 944 Thousand GBP | 102.58% |
| 2008 | 466 Thousand GBP | 119.81% |
| 2007 | 212 Thousand GBP | 5200.0% |
| 2006 | 4000.00 GBP | -98.72% |
| 2005 | 313 Thousand GBP | 1547.37% |
| 2004 | 19 Thousand GBP | 0.0% |
| 2003 | - GBP | -100.0% |
| 2002 | 11 Thousand GBP | 22.22% |
| 2001 | 9000.00 GBP | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q1 | 5.94 Million GBP | 43.73% |
| 2023 Q2 | 11.88 Million GBP | 100.0% |
| 2023 FY | 23.24 Million GBP | 140.83% |
| 2023 Q4 | 11.35 Million GBP | 100.0% |
| 2023 Q3 | 5.67 Million GBP | -52.23% |
| 2022 Q2 | 5.51 Million GBP | 100.0% |
| 2022 Q3 | 2.06 Million GBP | -62.52% |
| 2022 FY | 9.65 Million GBP | 228.22% |
| 2022 Q1 | 2.75 Million GBP | 344.92% |
| 2022 Q4 | 4.13 Million GBP | 100.0% |
| 2021 Q3 | 712.5 Thousand GBP | -69.3% |
| 2021 Q2 | 2.32 Million GBP | 206.2% |
| 2021 Q4 | 620 Thousand GBP | -12.98% |
| 2021 Q1 | 758 Thousand GBP | -58.49% |
| 2021 FY | 2.94 Million GBP | -19.11% |
| 2020 Q4 | 1.82 Million GBP | 100.0% |
| 2020 Q1 | 905 Thousand GBP | 0.0% |
| 2020 Q2 | 1.81 Million GBP | 100.0% |
| 2020 FY | 3.63 Million GBP | -11.81% |
| 2020 Q3 | 913 Thousand GBP | -49.56% |
| 2019 Q2 | 1.57 Million GBP | 0.0% |
| 2019 FY | 4.12 Million GBP | 49.22% |
| 2019 Q1 | 1.57 Million GBP | 62.09% |
| 2018 Q1 | 648.5 Thousand GBP | -11.53% |
| 2018 FY | 2.76 Million GBP | 1.02% |
| 2018 Q4 | 972 Thousand GBP | 0.0% |
| 2018 Q2 | 1.29 Million GBP | 100.0% |
| 2017 Q2 | 736.5 Thousand GBP | 0.0% |
| 2017 Q4 | 733 Thousand GBP | 0.0% |
| 2017 FY | 2.73 Million GBP | 26.33% |
| 2017 Q1 | 736.5 Thousand GBP | 16.72% |
| 2017 Q3 | 733 Thousand GBP | -0.48% |
| 2016 Q2 | 558.5 Thousand GBP | 0.0% |
| 2016 FY | 2.16 Million GBP | 19.42% |
| 2016 Q3 | 631 Thousand GBP | 12.98% |
| 2016 Q4 | 631 Thousand GBP | 0.0% |
| 2016 Q1 | 558.5 Thousand GBP | 6.58% |
| 2015 Q4 | 524 Thousand GBP | 0.0% |
| 2015 FY | 1.81 Million GBP | -42.99% |
| 2015 Q3 | 524 Thousand GBP | -3.68% |
| 2015 Q2 | 544 Thousand GBP | 0.0% |
| 2015 Q1 | 544 Thousand GBP | 50.07% |
| 2014 Q2 | 400.5 Thousand GBP | 0.0% |
| 2014 Q1 | 400.5 Thousand GBP | -1.96% |
| 2014 Q4 | 362.5 Thousand GBP | 0.0% |
| 2014 FY | 3.18 Million GBP | 17.78% |
| 2014 Q3 | 362.5 Thousand GBP | -9.49% |
| 2013 FY | 2.7 Million GBP | -13.74% |
| 2013 Q2 | 775 Thousand GBP | 0.0% |
| 2013 Q3 | 408.5 Thousand GBP | -47.29% |
| 2013 Q4 | 408.5 Thousand GBP | 0.0% |
| 2013 Q1 | 775 Thousand GBP | 34.78% |
| 2012 Q4 | 575 Thousand GBP | 0.0% |
| 2012 FY | 3.13 Million GBP | 28.02% |
| 2012 Q3 | 575 Thousand GBP | 0.0% |
| 2011 FY | 2.44 Million GBP | 18.29% |
| 2010 FY | 2.06 Million GBP | 118.96% |
| 2009 FY | 944 Thousand GBP | 102.58% |
| 2008 FY | 466 Thousand GBP | 119.81% |
| 2007 FY | 212 Thousand GBP | 5200.0% |
| 2006 FY | 4000.00 GBP | -98.72% |
| 2005 FY | 313 Thousand GBP | 1547.37% |
| 2004 FY | 19 Thousand GBP | 0.0% |
| 2003 FY | - GBP | -100.0% |
| 2002 FY | 11 Thousand GBP | 22.22% |
| 2001 FY | 9000.00 GBP | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -47.385% |
| SQZ Biotechnologies Company | 21.47 Million USD | -8.236% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -35268.488% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -27.605% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 81.093% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -293.883% |
| Marizyme, Inc. | 645.81 Thousand USD | -3499.666% |
| Genus plc | 668.8 Million USD | 96.524% |
| Pharming Group N.V. | 245.31 Million USD | 90.524% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -23383.241% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -5567.719% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -30184.91% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -58726.358% |
| MultiCell Technologies, Inc. | 49.32 USD | -47134936.496% |
| ONE Bio Corp. | 52.29 Million USD | 55.547% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 53.245% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | 21.455% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -4068.295% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -33110.0% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -30599.646% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -3430.296% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.842% |
| Agentix Corp. | - USD | -Infinity% |
| Enzolytics Inc. | 52.79 Thousand USD | -43931.745% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -3720.221% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 98.104% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -1103.261% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -16476.347% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 97.231% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -131827.813% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -2229.998% |
| EV Biologics, Inc. | 48.9 Thousand USD | -47439.877% |
| Q BioMed Inc. | 284.35 Thousand USD | -8075.43% |
| Capstone Therapeutics Corp. | 48.35 Million USD | 51.923% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 83.979% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -39.325% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -2326927.027% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -9727.105% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -3665.404% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -9727.105% |
| Affymax, Inc. | 1.36 Million USD | -1598.101% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -198.459% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -4807.226% |
| SYBLEU INC | 11.69 Thousand USD | -198660.26% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -178723.077% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -58702.55% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -598.108% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -248.792% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -2137.44% |
| Gelesis Holdings, Inc. | 25.76 Million USD | 9.78% |
| CSL Limited | 14.8 Billion USD | 99.843% |
| Cellectis S.A. | 755 Thousand USD | -2979.073% |